Drug Discovery

#Collaboration #Drug candidates #Drug development #Drug discovery

Call for application: AI for antibody design 

German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges.  The chosen AION Labs startup… Read More

#News

#Clinical trials #Data #Drug discovery #Life sciences

Clinical trials, the pandemic and technology 

Listen to this article on the DDW Podcast: Chris Sigley, CEO of Arkivum, says the transformation of clinical trials demands a transformed approach to trial data  The pandemic has created manifold challenges for clinical trials, but it has also proved a transformational force. The life sciences… Read More

#Exclusive Content #Trends & Analysis

#Drug development #Drug therapy

Oral GnRH antagonist licenced for treatment of uterine fibroids

Gedeon Richter has been granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA) for relugolix combination therapy (Ryeqo), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.   The decision reportedly makes the relugolix combination therapy the first oral gonadotropin-releasing hormone… Read More

#News

#AI / data analytics / healthtech / informatics #Biosciences #Drug development #Therapeutics

Analytical challenges when characterising complex molecules

Michael-John O’Connor, Director of Biochemical Services at BioPharmaSpec, discusses analysing biosimilars, glycosylated mAbs and PEGylated proteins with Lu Rahman.  LR: Outline the importance of bio-molecules in drug discovery. What is their potential within therapeutic development?    MJOC: The FDA’s recent approval of Biocon’s Semglee (long acting Insulin glargine) is the first example of… Read More

#Exclusive Content #News

#AI #AI / data analytics / healthtech / informatics #Drug design #Drug development #Drug discovery

AI round-up: the expanding influence of AI in drug discovery 

Artificial intelligence (AI) is intelligence demonstrated by machines, as opposed to intelligence demonstrated by animals (including humans). According to a report by IDTechEx, the application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. They… Read More

#Editor's Choice #Exclusive Content #News

#Assays #Drug discovery #High throughput screening #Technology

Case study outlines how to create more therapeutic opportunity

Pairing the right small molecule library with innovative high-throughput screening creates more therapeutic opportunity, this SAMDI Tech case study shows.  Finding an encouraging drug lead that selectively engages a target of interest is the result of several matches that lead to successful drug discovery programmes, including: … Read More

#News

#Drug development #Drug discovery #Drug targets #Protein chemistry / Proteomics #Research

Trivalent PROTACs more potent in targeted protein degradation 

Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation. The research is published in Nature Chemical Biology.  Targeted protein degradation is an area of chemical biology that is said to be revolutionising drug discovery. It involves… Read More

#News

#Biosciences #Cancer research #Drug discovery #Rare disease

RareCan receives approval to establish BioResource at Newcastle University 

RareCan has received approval from the NHS Research Ethics Committee to establish its BioResource at Newcastle University, which will store tissue samples from rare cancer patients collected during surgery, will be accessible to scientists around the globe undertaking research into the prevention, diagnosis or treatment of rare cancers. This reduces… Read More

#News

#Collaboration #Drug development

Ferrer and Treeway collaborate to develop treatment for ALS

Ferrer and Treeway have entered into a licence agreement for the development and commercialisation of an oral formulation of edaravone (TW001/FNP122) for Amyotrophic Lateral Sclerosis (ALS) in certain territories, including Europe and some Asian countries.   Ferrer is responsible for advancing the development and commercialisation of the product and will make royalty payments to Treeway at certain milestones. The deal… Read More

#News

#Collaboration #Drug discovery #Funding #Research

This week in drug discovery (18-22 October) 

News round-up by DDW’s Megan Thomas for 18-22 October  DDW’s Megan Thomas has selected five stories which highlight the opportunities in the drug discovery sector.   1. Researchers receive $4 million for exceptional junior scientists  Two Mount Sinai cancer researchers will receive $4… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Drug discovery #Pharmaceuticals #Pharmacology

Apeiron Biologics begins Covid-19 trial for inhaled drug candidate

Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.   The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More

#News

#Automation / robotics #Drug discovery #Drug targets

Arctoris’ automated platform accelerates drug discovery

This paid-for advertorial by Arctoris appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   Oxford-headquartered Arctoris progresses programmes from target to hit, lead, and candidate with superior efficiency, accuracy, and confidence. Key to the company’s capabilities is the unique combination… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Assay #Drug discovery #Electronic Lab Notebooks (ELN) #Research #Screening

Digitalisation of VIB’s biomedical research with CDD Vault 

This paid-for advertorial by CDD Vault appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   For any research-based organisation in the life sciences arena, experimental data is the key to deriving biological and biochemical insight and understanding,… Read More

#Exclusive Content

#Drug discovery #R&D #Research

Brochure: Cubis laboratory balances in vaccine R&D 

A new brochure by Sartorius is now available to download.   Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. Until today, various vaccines against several crucial diseases (including influenza, chicken pox, or HPV) have been developed that save… Read More

#News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Learn about immunophenotyping and advanced cell function assays

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News

#Drug discovery #Oncology #Organ-on-a-chip

CN Bio service offers support for oncology drug discovery

CN Bio has launched an oncology service which it says is in response to the global need to improve cancer drug discovery approval rates.  Understanding the relationship between pharmacokinetics, pharmacodynamics (PK/PD) and efficacy is critical to the successful development of new medicines, but at present this relationship is primarily investigated using… Read More

#News